Clinical Research

The University of Wisconsin Department of Dermatology conducts clinical research on a wide range of topics in both children and adults. Use the links below to jump to sections of our Clinical Research website.

Ongoing Clinical, Translational and Therapeutic Research

Back to top

Histologic Analysis of Onychomycosis with Clinical Correlations

In this medical record review, we will measure the density of fungus in the nails of patients previously diagnosed with onychomycosis with a software program and correlate this to the clinical severity of onychomycosis. The response to treatment will be used to explore whether the density of fungal infection is an independent predictor of response to treatment. Characterization and assessment of the anatomic location of fungus in biopsies of nails of the same population will be investigated as well, including common subtypes of onychomycosis.

Study Type: Non-Intervention
Category: N/A
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Principal Investigator and Contact Information

photo of molly hinshawMolly Hinshaw, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Histologic Analysis of Onychomycosis with Clinical Correlations

Back to top

Utilization of Dermatopathology Laboratory Archival Tissue for Feasibility Research

This protocol allows the use of de-identified diagnostic samples in exploratory or feasibility testing. The University of Wisconsin Hospital and Clinics (UWHC) Dermatopathology laboratory collects and stores residual diagnostic fresh tissue samples, which can be preserved as paraffin-embedded, frozen tissue, or as slides. Upon request the Department of Dermatology can provide investigators with samples of these tissues for exploratory or feasibility testing prior to their application for a separate IRB approved protocol.

Study Type: Non-Intervention
Category: N/A
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Principal Investigator and Contact Information

Beth Drolet, MD. ChairBeth Drolet, MD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Utilization of Dermatopathology Laboratory Archival Tissue for Feasibility Research

Back to top

Mechanism for Cancer Development and Progression

This protocol utilizes de-identified human pathological specimens such as begin and cancerous tissues, tissue microarrays (TMAs), established cell lines, primary cells and tissue arrays in ongoing research to understand the mechanisms of cancer development and progression, to identify novel biomarkers and approaches for the management of these diseases.

Study Type: Non-Intervention
Category: Cutaneous Oncology
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Principal Investigator and Contact Information

Nihal Ahmad, PhD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Mechanism for Cancer Development and Progression

Back to top

Utilization of Dermatopathology Laboratory Archival Tissue for Feasibility Research

This protocol allows the use of de-identified diagnostic samples in exploratory or feasibility testing. The University of Wisconsin Hospital and Clinics (UWHC) Dermatopathology laboratory and the UW Skin Disease Research Center (SDRC) collects and stores residual diagnostic fresh tissue samples, which can be preserved as paraffin-embedded, frozen tissue, or as slides. Investigators many request samples of these tissues for exploratory or feasibility testing prior to their application for a separate IRB approved protocol or for use with an IRB approved protocol.

Study Type: Non-Intervention
Category: N/A
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Principal Investigator and Contact Information

Beth Drolet, MD. ChairBeth Drolet, MD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Utilization of Dermatopathology Laboratory Archival Tissue for Feasibility Research

Back to top

Cutaneous Crohn Disease: Retrospective Review of Clinical Features, Disease Course, Treatment, and Outcomes

This study will better characterize the epidemiology and natural course of cutaneous Crohn disease in the United States with a specific focus on metastatic Crohn disease. It will describe the patient characteristics, the correlation between clinical and histopathologic features, potential disease triggers, long-term patient outcomes (e.g., prevalence and timing of intestinal disease), treatment patterns and response to therapy, complications, and health care utilization. Additionally, this study may provide insight into potential triggers of cutaneous Crohn disease.

Study Type: Non-Intervention
Category: Inflammatory Dermatoses
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Principal Investigator and Contact Information

photo of bridget shieldsBridget Shields, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Cutaneous Crohn Disease: Retrospective Review

Back to top

Epidemiology of Chilblains Before & During the COVID-19 Pandemic

The purpose of our study is to describe the incidence and demographics of chilblains visits before and during the pandemic. Additionally, we plan to examine trends among ambient temperature, community infection rates and presentation to health care for pandemic-associated chilblains during the pandemic.

Study Type: Non-Intervention
Category: COVID-19
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Principal Investigator and Contact Information

Beth Drolet, MD. ChairBeth Drolet, MD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Epidemiology of Chilblains Before & During the COVID-19 Pandemic

Back to top

Assessing the Sensitivity and Specificity of Imaging in Cutaneous Squamous Cell Carcinoma to Detect Nodal Metastasis Using Lymph Node Biopsy Results as the Gold Standard

The purpose of our study is to establish the sensitivity and specificity of imaging to detect nodal metastasis in cutaneous squamous cell carcinoma. We aim to evaluate the sensitivity and specificity of imaging modalities in detection of nodal metastasis for cutaneous SCC with use of lymph node biopsy results as the gold standard.

Study Type: Non-Intervention
Category: Cutaneous Oncology
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Principal Investigator and Contact Information

Gloria Xu, MD, PhD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Assessing the Sensitivity and Specificity of Imaging in Cutaneous Squamous Cell Carcinoma

Back to top

Clinical, Immunologic, and Genetic Characterization of Severe Mucocutaneous Reactions

Our goal is to develop a better understanding of the cause of severe blistering skin reactions or related disorders. We hope that by better understanding the cause we may be able to improve care for people who are affected by these skin reactions.

Study Type: Non-Intervention
Category: Skin Reactions
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Eligibility Criteria

  • Individual of any age from infant to adult
  • Diagnosis of severe mucocutaneous reactions or related disorders including reactive infectious mucocutaneous eruptions (RIME), Mycoplasma-induced rash and mucositis (MIRM), erythema multiforme (EM), Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), Drug-Induced Epidermal Necrolysis (DEN) and other disorders on this spectrum. Participants with recurrent disease should have at least one episode that was diagnosed by a dermatologist or pediatric dermatologist.
  • Medical records available and willing to provide access to the study team

Principal Investigator and Contact Information

Beth Drolet, MD. ChairBeth Drolet, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Clinical, Immunologic, and Genetic Characterization of Severe Mucocutaneous Reactions

Back to top

Metabolic Profiling of Leukemic Cells Through Isotope Tracing in Patients with Chronic Lymphocytic Leukemia (CLL)

Our goal is to create and distribute de-identified tissue microarrays consisting of benign growths, usually hyperpigmented or skin-colored macules, papules, or small plaques probably derived from proliferating altered melanocytes (nevus cells) and malignant melanoma. The tissue microarrays will be disturbed, upon approval, to investigators performing skin disease research though the UW Skin Disease Research Center.

Study Type: Non-Intervention
Category: Cell Metabolism
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

Participation Includes

  • Fasting for 8-12 hours
  • Physical exam
  • 6 blood collections
  • Bone marrow aspiration performed by the study doctor (depending on your CLL burden)

Eligibility Criteria
Inclusion (Includes, but is not limited to)

  • At least 18 years of age or older
  • CLL Subject : Diagnosis of CLL and have not had previous treatment for CLL
  • Healthy Subject: Healthy person

Exclusion (Includes, but is not limited to)

  • History of diabetes
  • Cannot be on antihyperglycemic therapy
  • Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc.

Principal Investigator and Contact Information

Stefan Schieke, MD
Principal Investigator
Dana Doutelle – University of Wisconsin
Carbone Cancer Center
Lymphoma Clinical Research Group
lymphoma@uwcarbone.wisc.edu
(608) 263-7521
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

NCT ID: NCT04785989

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Metabolic Profiling of Leukemic Cells

Back to top

Creation of Benign Nevi and Melanoma Tissue Microarray for Distribution Through the UW Skin Disease Research Center

Our goal is to create and distribute de-identified tissue microarrays consisting of benign growths, usually hyperpigmented or skin-colored macules, papules, or small plaques probably derived from proliferating altered melanocytes (nevus cells) and malignant melanoma. The tissue microarrays will be disturbed, upon approval, to investigators performing skin disease research though the UW Skin Disease Research Center.

Study Type: Non-Intervention
Category: Melanoma
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Nihal Ahmad, PhD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Creation of Benign Nevi and Melanoma Tissue

Back to top

Molecular Markers for Melanoma Progression

Cutaneous melanoma is the deadliest form of skin cancer. If diagnosed early and treated appropriately before the cancer becomes aggressive, melanoma is often curable. However, there are no known biological markers to reliably assess the aggressiveness of melanoma. The goal of this project is to assess the value of novel markers in predicting melanoma tumor aggressiveness.

Study Type: Non-Intervention
Category:  Melanoma
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Picture of Vijay Setaluri, PhDVijayasaradhi Setaluri, PhD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Molecular Markers for Melanoma Progression

Back to top

Histopathologic Characteristics and Clinical Features of Nail Unit Squamous Cell Carcinoma: An Institutional Experience

Our goal is to facilitate the diagnosis of nail unit SCC, characterize its histologic and clinical features, and better understand patient outcomes, we will characterize the histopathologic changes of nail squamous cell carcinoma in a series of patients with a specific focus on the frequency of the finding of “atypical parakeratosis” in nail plate clippings and nail biopsies of histologically confirmed cases of nail unit SCC.

Study Type: Non-Intervention
Category: Squamous Cell Carcinoma
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

photo of molly hinshawMolly Hinshaw, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Histopathologic Characteristics and Clinical Features of Nail

Back to top

Revealing Accumulative Gene Mutations in Basal Cell Nevus Syndrome to Achieve Pathway-specific Therapies

The purpose of this study is to Identify the accumulative gene mutations in people with basal cell nevus syndrome with aging and sun exposure in order to better characterize their genotype for targeted specific therapies.

Study Type:
Non-Intervention
Category: Basal Cell Carcinoma
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Gloria Xu, MD, PhD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Revealing Accumulative Gene Mutations

Back to top

A Phase 3B, Multicenter, Open-label Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Moderate to Severe Plaque Psoriasis

The purpose of this research study is to test the long-term effects on child and adolescent psoriasis of an investigational (being tested) drug called apremilast, which is the same study drug the child received in the study he/she is about to complete or has just completed (CC-10004-PPSO-003).

Study Type: Intervention
Category: Inflammatory Skin Disorders
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Lisa Arkin, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

NCT ID: NCT03701763

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Apremilast (CC-10004) in Pediatric

Back to top

Vascular and Skin Eruptions Temporally Associated with COVID-19

During the COVID-19 pandemic, there has been an increase in number of children and young adults with painful red to purple lesions, blisters, and ulcers on the feet, toes and fingers around the world. The purpose of this research study is to understand if these skin changes are a sign of COVID-19 infection or a response to the virus.

Study Type: Non-Intervention
Category: COVID-19
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Donating up to 4 blood samples
  • Donating a spit sample
  • Collection of information from your medical record

Eligibility Criteria

Inclusion

  • Individual of any age from infant to adult
  • affected Patients: Diagnosed with a possible SARS-CoV-2 related vascular or skin eruption
  • Health Patients: Not diagnosed with or history of possible SARS-CoV-2 related vascular or skin eruption or COVID disease

Principal Investigator and Contact Information

Lisa Arkin, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#COVID-Toes

Back to top

Characterization of Metabolic Factors in Lymphoma and Leukemia Dissemination

The goal of this study is to determine the role of metabolic dynamics as a regulator of leukemia and lymphoma cell invasion and disease dissemination. Among several factors influencing survival outcomes, the degree of dissemination and presence of extramedullary and extra nodal spread critically influences therapeutic strategy. Despite the clinical importance, mechanisms controlling dissemination are poorly understood. Emerging evidence suggests that cancer cell metabolism is a critical factor in disease evolution, progression and treatment response. This study will characterize how distinct metabolic profiles promote various functional states and phenotypes during progression and dissemination of leukemia and lymphoma.

Study Type: Non-Intervention
Category: Cutaneous T Cell Lymphoma
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Stefan Schieke, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#metabolic-factors-in-lymphoma

Back to top

Changes in CTCL landscape and T-cell receptor clonality dynamics

Recent work in lymphoma and leukemia indicates that the current clinical practice of identifying malignant cells based on the presence or absence of cell surface markers (the “immunophenotype”) inappropriately bins large subsets of malignant cells that otherwise have unique properties, including subtle differences in expression of both known and possibly heretofore undiscovered cell surface markers. The goal of this project is to trace the evolution of malignant cells in patients as they progress through treatment and encounter treatment resistance and/or relapse. The results of this work may help diagnose aggressive disease earlier and may help better understand the basis of treatment resistance.

Study Type: Non-Intervention
Category: Cutaneous T Cell Lymphoma
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Stefan Schieke, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#changes-in-CTCL-landscape

Back to top

Characterizing the Immunophenotypic Landscape in the Leukemic Compartment During Disease Progression and Treatment in Cutaneous T cell Lymphoma

The primary aim of this study is to determine the qualitative and quantitative characterization of the leukemic compartment using the t-SNE (t-Distributed Stochastic Neighbor Embedding) clustering algorithm to conventional gating. Results of this work may help to diagnose aggressive disease earlier and better understand the basis of treatment resistance and allow for a clinical performance comparison between conventional manual gating and an automated algorithm leading to significant benefits and applications in CTCL management.

Study Type: Non-Intervention
Category: Cutaneous T Cell Lymphoma
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Stefan Schieke, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Immunophenotypic-Landscape-of-Leukemia

Back to top

Evaluation of Circulating Tumor Cells in Melanoma

The aim of this study is to develop and optimize a microfluidic immunosensor array method for detection and capture of intact melanoma CTC in patients diagnosed with primary melanoma.

Study Type: Non-Intervention
Category: Melanoma
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Eligibility Criteria

Inclusion

  • At least 18 years of age or older
  • Melanoma Subject: Diagnosis of Stage I-IV melanoma
  • Healthy Subject: Healthy person

Exclusion

  • Currently in prison or institutionalized (psychiatric)
  • Healthy Subject: history of melanoma, other cancer, or inflammatory skin disease

Principal Investigator and Contact Information

Picture of Vijay Setaluri, PhDVijayasaradhi Setaluri, PhD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Circulating-tumor-cells-in-melanoma

Back to top

Light treatment Effectiveness (LITE) Study

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based NB-UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at home or the office are both common treatments for psoriasis, but it is not known how well they compare to one another.

Study Type: Intervention
Category: Psoriasis
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Receive either at home or in office phototherapy about 3 times a week for up to 12 weeks
  • If selected for at home, a phototherapy machine will be shipped to your home
  • Periodically complete electronic questionnaires

Eligibility Criteria

Inclusion (Includes, but is not limited to)

  • Age 12 or older
  • Plaque or guttate psoriasis predominantly located on trunk and/or extremities
  • Is able to travel 3 times a week and/or has space in home for machine (since you will be randomly assigned)

Exclusion (Includes, but is not limited to)

  • Known history of lack of efficacy to phototherapy
  • Treated with phototherapy 14 days prior to baseline visit
  • History of photosensitivity or autoimmune disease such as lupus or dermatomyositis

Principal Investigator and Contact Information

Margo Reeder, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#LITE-Study

NIH ID

https://clinicaltrials.gov/ct2/show/NCT03726489

Back to top

USCLC National Cutaneous Lymphoma Registry

The primary goal of the USCLC is to establish a registry of patients with cutaneous lymphoma in the United States. This is particularly important as some of the types of cutaneous lymphoma are very rare and it is only with a collaborative effort across multiple institutions and sites that enough data can be generated on each of these types of cancer.

Study Type: Non-Intervention
Category: Cutaneous T-Cell Lymphoma
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Data collected from your medical record about your disease
  • Log into the registry to complete online questionnaires about how your disease affects your life

Eligibility Criteria

  • Diagnosis of Cutaneous Lymphoma

Principal Investigator and Contact Information

Gary S. Wood, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#USCLC-National-Cutaneous-Lymphoma-Registry

Back to top

Multicenter Phenotype-Genotype Analysis of Vascular Anomalies and Related Syndromes

The purpose of this research study is to develop a better understanding of the cause and natural history of vascular anomalies and related syndromes. We are doing this study because we hope that by better understanding the cause we may be able to improve care for people who are affected by these anomalies and related syndromes.

Study Type: Non-Intervention
Category: Venous Malformations
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Data collected from your medical record about your disease
  • Optional Skin Biopsy
  • Optional Blood Sample
  • Optional Spit Sample
  • Optional Cheek Swab
  • Optional donation of excess tissue collected from a surgery

Eligibility Criteria

  • Individual of any age from infant to adult
  • Diagnosed with a vascular anomaly or discrepancy of growth

Principal Investigator and Contact Information

Beth Drolet, MD. ChairBeth Drolet, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Multicenter-Phenotype-Genotype-Analysis

Back to top

Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography

The purpose of this research study is to develop a better understanding of vascular stains and to improve the usual laser treatment for your vascular stain by using optical coherence tomography (OCT). We are doing this study because we hope that by better understanding vascular stains and using OCT, we may be able to improve care for people who are affected by these stains.

Study Type: Intervention
Category: Vascular Anomalies and Birthmarks
Enrollment Status: On Hold

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • One-time blood, spit, and/or skin sample
  • Complete a short questionnaire at each visit
  • Length of study varies

Eligibility Criteria

  • Individual of any age from infant to adult
  • Diagnosed with a vascular stain on any anatomic location based on the discretion of the study physician
  • Has elected to receive standard of care laser treatment for their vascular stain

Principal Investigator and Contact Information

Lisa Arkin, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Optical-Coherence-Tomography

NIH ID

NCT04772911

Back to top

An Open-Label, Repeat-Application, Intra-Subject, Dose Escalation (Part 1) Followed by a Randomized, Double-Blind, Placebo-Controlled (Part 2) Trial of Topical VT30 in Subjects with Venous, Lymphatic or Mixed Malformations Associated with PIK3CA or TEK Genetic Mutations

The main purpose of the study is to find out the safety and tolerability of VT30 gel after multiple doses of topical administration in Venous Malformations (VM), Lymphatic Malformations (LM), and Venolymphatic Malformations (VLM) lesions of the skin.

Study Type: Intervention
Category: Vascular Anomalies and Birthmarks
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Application of VT30 Topical Gel (the study drug) for 4 weeks on the treatment area
  • If you choose to participate in part 2: additional 12 weeks of VT30 (or placebo) Topical Gel

Eligibility Criteria

Inclusion (includes, but is not limited to)

  • Have a clinically or phenotypically defined VM, LM, or mixed VLM affecting the skin
  • Be at least 16 to 60 years of age
  • Lesions must take up 140 to 700 cm2 (22 to 108 in2)

Exclusion (includes, but is not limited to)

  • Treatment area is within 6cm of an eye, or 3 cm of a nostril or the mouth
  • Known systemic hypersensitivity to the VT30 drug substance
  • Major surgery or significant infection within 8 weeks of Screening
  • Presence of ulcerations on the target-treatment lesion

Principal Investigator and Contact Information

Beth Drolet, MD. ChairBeth Drolet, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Topical-VT30-in-Subjects-with-Venous-Malformations

NIH ID

NCT04409145

Back to top

FAS Apoptotic Pathway Abnormalities in Cutaneous T-Cell Lymphoma (Mycosis Fungiodes (MF) and Sezary Syndrome (SS))

The purpose of this research study is to learn how CTCL and related disorders develop and progress. We are doing this research because having a better understanding of CTCL may help us develop new diagnostic and treatment tools in the future to improve the management and prognosis of individuals suffering from CTCL.

Study Type: Non-Intervention
Category: Cutaneous T-Cell Lymphoma
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Agreement for the research study to use left-over tissue from your standard-of-care biopsies
  • Optional Blood Sample

Eligibility Criteria

Inclusion

  • Individuals with cutaneous lymphoproliferative disorders (CLPDs) and potential precursor conditions like chronic dermatitis
  • Controls including inflammatory skin diseases (e.g. acute dermatitis, psoriasis, drug rashes, normal skin).

Exclusion

  • Women who are pregnant
  • Treatment within 2 weeks prior to biopsy

Principal Investigator and Contact Information

Gary S. Wood, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#FAS-Apoptotic-Pathway-Abnormalities-in-CTCL

Back to top

Therapeutic Targeting of Metabolic Adaptation to Metformin in Chronic Lymphocytic Leukemia (CLL)

The purpose of this research study is to determine how blood may react to different cancer therapy drugs. We are doing this research because we are looking for novel ways to better treat lymphocytic leukemia.

Study Type: Non-Intervention
Category: Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • One-time blood sample

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Chronic Lymphocytic Leukemia (CLL) Stage I – III. Please call for details.

Exclusion

  • Evidence of T11, 14, and/or Cyclin D1 staining from flow cytometry results
  • Diagnosis of atypical CLL

Principal Investigator and Contact Information

Stefan Schieke, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Therapeutic-Targeting-of-Metabolic-Adaptation-to-Metformin-in-CLL

Back to top

Quantification of Formaldehyde in Textiles: Impact on Allergic Contact Dermatitis

The purpose of this research study is to determine the amount of formaldehyde in clothing that will cause allergic contact dermatitis in people allergic to formaldehyde. We are doing this research because approximately 10% of patients with contact dermatitis are allergic to formaldehyde and many of these patients are allergic to the formaldehyde found in clothing. Because the amount of formaldehyde in clothing that may cause an allergic reaction is unknown, this presents challenges to those who are allergic to formaldehyde when buying clothing. This research study will help us determine formaldehyde amounts in clothing and which of those amounts will most likely cause allergic reactions. Results from this study could provide researchers with information on how chemicals (formaldehyde) in clothing cause allergic contact dermatitis.

Study Type: Non-Intervention
Category: Contact Dermatitis
Enrollment Status: On Hold

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Patch testing with both Finn Chambers and fabric swatches over a period of a week

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Presented to UW Dermatology clinic within last 3 years
  • Patch tested with positive reaction to formaldehyde 2% aqueous (graded as 1,2, or 3 at > 96 hours after placement)
  • Currently symptom-free from allergic contact dermatitis
  • Not on any immunosuppressive medication which could interfere with interpretation of the patch testing

Exclusion

  • Women who are pregnant

Principal Investigator and Contact Information

Margo Reeder, MD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Quantification-of-Formaldehyde-in-Textiles

Back to top

Characterization of the Virome and Microbiome of Normal and Neoplastic Skin of Organ Transplant Recipients

The purpose of this research study is to look at the relationship between cutaneous human papillomaviruses and squamous cell carcinomas (SCC) in people who either have or have not had an organ transplant. We are doing this research because we would like to address if drugs which works against the body’s immune (protective) response, often used in organ transplant patients inclines them to HPV infections versus people who have not taken these drugs. Also, we would like to see if HPVs present in SCCs are the same as in normal skin.

Study Type: Non-Intervention
Category: Squamous Cell Carcinoma
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Willing to donate leftover tissue from the removal of your squamous cell carcinoma (SCC)

Eligibility Criteria

  • 18 years of age or older
  • Having SCC removed that is visible and palpable with a tumor size of at least 1cm

Principal Investigator and Contact Information

Gloria Xu, MD, PhD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Virome-and-Microbiome-of-Skin-of-Organ-Transplant-Recipients

Back to top

Role of SIRT3 and PLK4 in Melanoma Development and Progression

The main purpose of this study is to collect and use a portion of the melanoma tissue removed during a standard of care biopsy or surgical removal. This would be residual tissue, which would normally be stored and kept with your medical records. This melanoma tissue collected will be used to do research on understanding how skin cells change and progress into melanoma.

Study Type: Non-Intervention
Category: Melanoma
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Participation in this study will consist of donating a portion of your standard-of-care skin biopsy/excision tissue sample.

Eligibility Criteria

  • 18 years of age or older
  • United States of America Veteran
  • Diagnosis of primary or metastatic melanoma
  • Undergoing a standard-of-care removal of subcutaneous melanoma tumor

Principal Investigator and Contact Information

Nihal Ahmad, PhD
Principal Investigator
Christina Sheehan
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#SIRT3-and-PLK4-in-Melanoma-Development-and-Progression

Back to top

Histologic Evaluation of Cutaneous SCC Debulk Specimens Prior to MMS for Accurate Staging and Biomarker Correlation

The main purpose of this study is to research on the current methods of grading skin cancer and how that relates to the long term health outcomes of patients with SCC including rates of metastasis (spread).

Study Type: Non-Intervention
Category: Squamous Cell Carcinoma
Enrollment Status: Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Participation Includes

  • Participation in the research study involves the collection of information from your medical records regarding your skin cancer and will not require any additional time.
  • If tissue is sent to the pathology lab after removal of your SCC, we would also like your permission to use a small portion for our research on proteins that play a role in SCC.

Eligibility Criteria

  • 18 years of age or older
  • Undergoing a standard-of-care removal of SCC in a dermatology clinic

Principal Investigator and Contact Information

Gloria Xu, MD, PhD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Histologic-Evaluation-of-Cutaneous-SCC-Debulk-Specimens-Prior-to-MMS

Back to top

North American Contact Dermatitis Group Registry

The North American Contact Dermatitis Group (NACDG) collects data on patch test results in combination with basic occupational and clinical information for the detection of delayed type hypersensitivity reactions to topical allergens. The data is used to answer questions about most frequent contact allergens, trends related to allergens and occupation, relatively new allergen frequency of reaction, or allergens increasing in frequency of allergic reactions reported.

Study Type: Non-Intervention
Category: Contact Dermatitis
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Margo Reeder, MD
Principal Investigator
Image of Heather NeilsHeather Neils
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#North-American-Contact-Dermatitis-Group-Registry

Back to top

Outcomes and Correlative Studies of Patch Testing in Dermatology

The purpose of this study is to examine patch test reactions to a variety of different allergens and to investigate reaction trends based on other clinical factors. The data will be used to provide physicians treating individuals with dermatitis information on how to improve the quality of care they provide through the UW Department of Dermatology.

Study Type: Non-Intervention
Category: Contact Dermatitis
Enrollment Status: Not Open to Enrollment

This is an accordion element with a series of buttons that open and close related content panels.

More Information

Principal Investigator and Contact Information

Margo Reeder, MD
Principal Investigator
Ellen Bruhn
Primary Contact
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Direct Link to this Study

dermatology.wisc.edu/research/clinical-research/#Outcomes-and-Correlative-Studies-in-Patch-Testing

Contact

Image of Heather Neils
Heather Neils
Clinical Trials Admin.
Dept. of Dermatology
hneils@dermatology.wisc.edu
608-287-2622

Fax: 608-287-2693

crest
Christina Sheehan
Clinical Trials Coord.
Dept. of Dermatology
csheehan@dermatology.wisc.edu
608-287-2622

Fax: 608-287-2693

crest
Ellen Bruhn
Clinical Trials Coord.
Dept. of Dermatology
clinicaltrials@dermatology.wisc.edu
(608) 287-2622

Fax: 608-287-2693

Clinical Investigators

Lisa M. Arkin, MD

Position title: Associate Professor and Director of Pediatric Dermatology

Beth Drolet, MD

Position title: Chair

Molly Hinshaw, MD

Position title: Associate Professor and Section Chief of Dermatopathology

Charlotte LaSenna, MD

Credentials: Assistant Professor

Ashley Privalle, MD

Position title: Assistant Professor

Margo Reeder, MD

Position title: Associate Professor and Medical Director of Quality Improvement

Stefan M. Schieke, MD

Position title: Assistant Professor, Dermatology Research Laboratories

Bridget Shields, MD

Position title: Assistant Professor

Gary Wood, MD

Position title: Professor and Founding Chair, Geneva F. and Sture Johnson Professor Emeritus

Yaohui (Gloria) Xu, MD, PhD

Position title: Associate Professor and Director of Micrographic Surgery and Dermatologic Oncology Fellowship

To Heal
To Educate
To Discover

Our Mission